A trial of directed therapy in younger patients with acute myeloid leukaemia: MRC AML 15
- Conditions
- eukaemiaCancerLeukaemia
- Registration Number
- ISRCTN17161961
- Lead Sponsor
- Cardiff University (UK)
- Brief Summary
2003 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12933575 results of a feasibility study 2010 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19965647 results 2010 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/20385793 pooled analysis of prognostic significance of rare recurring chromosomal abnormalities 2012 Results article in http://www.ncbi.nlm.nih.gov/pubmed/22875911 results 2013 Results article in http://www.ncbi.nlm.nih.gov/pubmed/23439754 results 2013 Results article in http://www.ncbi.nlm.nih.gov/pubmed/23940227 results 2014 Results article in http://www.ncbi.nlm.nih.gov/pubmed/24855211 results 2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29025912 results (added 25/07/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 3000
1. Any form of de novo or secondary AML
2. Suitable for intensive chemotherapy
3. Under 60 years
4. Written consent
1. Previous chemotherapy for AML
2. Blast transferration of CML
3. Pregnant or lactating
4. Abnormal liver function tests for Mylotarg randomisations
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> The main endpoints for each comparison will be:<br> 1. Complete remission (CR) achievement and reasons for failure (for induction questions)<br> 2. Duration of remission, relapse rates and deaths in first CR<br> 3. Overall survival<br> 4. Toxicity, both haematological and non-haematological, and quality of life<br> 5. Supportive care requirements (and other aspects of health economics)<br>
- Secondary Outcome Measures
Name Time Method ot provided at time of registration